Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Sudhir Valia (for himself and on behalf of Mrs. Raksha Valia) has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE FY16 results on May 30, 2016
Sun Pharmaceutical Industries Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2016, interalia, to transact the following business:- To consider and approve standalone and consolidated Audited Financial Results of the Company for the year ended March 31, 2016.- To consider recommendation of dividend for the year ended March 31, 2016 subject to the approval of the shareholders at the ensuing Annual General Meeting....
Not aware of adverse findings about manufacturing units of Ranbaxy: Sun Pharma
Based on our understanding of the matter, there is no truth to the assertions you are making, a Sun spokesperson said in an email to ET. Sun Pharma launches mobile app for asthma patients
RespiTrack seeks to enable doctors to track treatment progress of their patients and increase compliance to medication Ranbaxy sale: Malvinder, Shivinder Singh told to pay Rs 2,563 crore fine
Daiichi Sankyo, which finally exited the company in April 2014 by selling it to home-grown multinational Sun Pharmaceutical Industries, had filed the arbitration case in 2013 in Singapore. Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated May 04, 2016 titled "Sun Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis".
ICGEB, Sun Pharma tie-up to develop novel dengue drug
ICGEB and Sun Pharma will develop the drug, known as Cipa, following a registration process that consists of trials and studies that meet both Indian and international regulatory standards. ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue
Sun Pharmaceutical Industries Ltd has informed BSE regarding a Press Release dated May 04, 2016, titled "ICGEB & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue". Outcome of Allotment Committee Meeting
Sun Pharmaceutical Industries Ltd has informed BSE that the Allotment Committee of Directors at its meeting held on May 02, 2016, allotted 25,460 (Twenty Five Thousand Four Hundred and Sixty) equity shares of the Company of Re. 1/- (Rupee One Only) each, on exercise of stock options under the Sun Employee Stock Option Scheme - 2015.Accordingly, post the above allotment the paid-up equity share capital of the Company is Rs. 2,40,67,53,959/-... Sun Pharma Advanced board nod to rights issue allotment
Sun Pharma Advanced Research Company has informed the exchanges that the rights issue committee on Wednesday approved the allotment of 1.02 crore fully paid-up equity shares at 245 an equity share on...